J&J's Janssen Gets European Approval for Spravato
19 December 2019 - 10:32PM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
Thursday said the European Commission approved its Spravato nasal
spray for adults with treatment-resistant major depressive
disorder.
The drug maker said the approval covers Spravato in combination
with a selective serotonin reuptake inhibitor or serotonin and
norepinephrine reuptake inhibitor for adults with
treatment-resistant depression, meaning they haven't responded to
at least two different treatments.
Janssen said major depressive disorder affects about 40 million
people across Europe and is the leading cause of disability
worldwide.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 19, 2019 06:17 ET (11:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024